Valeo Pharma Inc. products

Asthma is a chronic inflammatory disease that causes the airways in the lungs to narrow and swell. Symptoms include wheezing, breathlessness, chest tightness, cough and asthma attacks (exacerbations).

Next generation dual therapy LABA/ICS. Partner with Novartis Pharma Canada.

RedescaTM is the only heparin biosimilar that is clinically tested, has the largest global patient exposure, and that supprts affordability (health care).

M-Eslon is a narcotic analgesic distributed by Valeo Pharma in Canada through a license from Ethypharm S.A.

Ametop Gel is indicated for percutaneous local anesthetic to produce anesthesia of the skin prior to venepuncture or venous cannulation, including intravenous injections of medications.

The first Parkinson’s Disease (PD) treatment in Canada since 2006, providing relief of symptoms during the off-phase in dopamine treated patients.

Yondelis® (trabectedin) is a novel marine-derived antitumor agent manufactured by PharmaMar S.A., based in Madrid, Spain. It exerts its anticancer effects primarily by inhibiting active transcription, a type of gene expression on which proliferating cancer cells are particularly dependent.